Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more




  • OnabotulinumtoxinA for Treatment of Chronic Migraines

    A pooled analysis of four clinical trials concluded that treatment with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks for up to five treatment cycles was efficacious, safe, and well tolerated for the prophylaxis of headache in adults with chronic migraine.
  • Does It Really Make a Difference What Weight-Reduction Diet You Choose?

    Since two-thirds of American adults are currently overweight or obese, we would all like to be able to help patients choose the best diet. The list of choices and categories is lengthy, with vocal advocates for the Atkins diet, the Zone diet, South Beach diet, Jenny Craig, Ornish, etc. Of course, were any of these diets sufficiently effective and easily adopted that they could gain widespread advocacy, we wouldnt be faced with such an obesity epidemic in the first place! So, apparently there is no simple answer. Among the choices we have, then, which one might be the best?
  • Naltrexone HCl and Bupropion HCl Extended-Release Tablets (Contrave ® )

    The FDA has approved another drug combination for the treatment of chronic weight management, combining two old drugs, naltrexone and bupropion, in a fixed combination. Naltrexone is an opioid antagonist and bupropion is a commonly prescribed antidepressant.
  • Do Telephone- and Internet-based Communications with Patients Increase Office Visits?

    In an integrated health plan and care delivery system, before and after a medical home redesign, proportional increases in copay-free secure messaging and telephone encounters were associated with additional primary care office visits for individuals with diabetes.
  • Tadalafil Tablets for BPH (Cialis)

    Tadalafil, Eli Lillyâs blockbuster drug for erectile dysfunction, has now been approved to treat signs and symptoms of benign prostatic hyperplasia. Tadalafil is the first drug of its class to be approved for this indication.
  • Hot Flash Treatment: 2011

    In a randomized, double-blind, placebo-controlled trial, clonidine and venlafaxine both proved superior to placebo in reducing hot flashes in breast cancer patients. The study was insufficiently powered to prove superiority of one drug over the other. However, venlafaxine produced earlier reductions and it appeared clonidine had more sustained effect (i.e., at 12 weeks of treatment).
  • Risk of Perioperative MI in Patients with Stents Undergoing Surgery

    The authors conclude that patients with coronary stents undergoing an invasive procedure are at high risk of perioperative cardiovascular and bleeding complications, and that these are associated with a high mortality.
  • Clinical Briefs By Louis Kuritzky, MD

    Recent retrospective studies in Europe have created concern because of an observed increased risk of cancer (hazard ratio = 1.55) in users of insulin glargine (GLAR) compared to nonusers.
  • Recommending the Appropriate Physical Activity to Your Patients

    A newly developed instrument to measure brief physical activity counseling in primary care demonstrates that physicians need to do a better job.
  • Height and Cancer Risk

    From a large cohort of women followed prospectively and with an adjunct meta-analysis of existing evaluable studies, a clearly demonstrated, nearly universal (i.e., across tumor types) incremental increase in cancer incidence was observed with advancing height.